AI and Cancer Research ── Cancer biology ── 2026-10-10
Cancer molecular biology and AI
- Abstract
Brain metastasis represents the most prevalent central nervous system tumor among adults and is associated with an unfavorable prognosis and reduced overall survival rates. A proportion of patients present with brain metastasis as the first manifestation of an unidentified primary tumor. However, conventional qualitative MRI evaluation remains inadequate for precisely identifying the primary origin of brain metastases. Therefore, this systematic review and diagnostic meta-analysis aimed to evaluate the diagnostic performance of MRI-based artificial intelligence models for predicting the primary tumor origin of brain metastases and to identify factors contributing to variability in their performance.
Journal IF: unknown (could not be matched)Reference: [No authors listed]. MRI-based artificial intelligence for primary tumor origin prediction in brain metastases: a systematic review and diagnostic meta-analysis. Open Science Framework. [Epub ahead of print]. doi:10.17605/osf.io/kz95c.Checked: Abstract only - Abstract
Trophoblast cell surface antigen 2 (TROP-2) is a transmembrane glycoprotein overexpressed across a range of epithelial malignancies, yet its clinical assessment still relies largely on invasive immunohistochemical analysis of biopsied tissues. In this study, we employed the PepMimic artificial intelligence platform to de novo design a TROP-2-targeting peptide, TR23, via binding interface mimicry, which was subsequently conjugated with DOTA and radiolabeled with 68Ga to yield the peptide-based PET probe [68Ga]Ga-DOTA-TR23. The tracer bound TROP-2 with nanomolar affinity (KD = 26.8 nM), showed selective cellular uptake in TROP-2-positive cells, and exhibited high radiochemical purity (>95%) with excellent stability in saline and serum. Micro-PET/CT imaging in pancreatic (BxPC-3), prostate (PC3), and thyroid (BCPAP) xenograft models revealed rapid, specific tumor accumulation with high contrast and low background uptake, while competitive blocking studies with excess unlabeled TR23 substantially suppressed tumor uptake, confirming receptor-mediated specificity. Quantitative analysis further demonstrated strong positive correlations between SUVmax and TROP-2 expression levels verified by immunohistochemistry across all three tumor types. Collectively, these findings establish [68Ga]Ga-DOTA-TR23 as a promising peptide-based PET tracer for rapid, specific, and quantitative imaging of TROP-2-positive tumors, and highlight the PepMimic-enabled strategy as a versatile platform for peptide-based probe discovery, supporting the translational potential of this tracer as a pan-cancer diagnostic agent for precision molecular imaging.
Journal IF-equivalent: 3.7 (OpenAlex 2-year mean citedness, value as of 2026-10-09, retrieved 2026-10-10; not the official Clarivate IF)Reference: Lin Z, Yang Z, Ma S, Lin X, Zhang Q, Miao W, et al. De Novo Design of a TROP-2-Targeting Peptide PET Tracer via AI-Guided Binding Interface Mimicry. Bioconjugate Chemistry. 2026 Oct 8 [Epub ahead of print]. doi:10.1021/acs.bioconjchem.6c00394.Checked: Abstract only